Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 8/20 | 0.45 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 7/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5010916 | 1.00 | USP2 (0.45) | USP2TSHRCYP3A4HSD17B10TACR1 | |
| SCHEMBL5012105 | 0.90 | USP2 (0.48) | USP2TSHRCYP3A4HSD17B10TACR1 | |
| SCHEMBL5012108 | 0.90 | USP2 (0.48) | USP2TSHRCYP3A4HSD17B10TACR1 | |
| SCHEMBL5012565 | 0.89 | TACR1 (0.50) | USP2TSHRCYP3A4HSD17B10TACR1 | |
| SCHEMBL5014228 | 0.89 | HIF1A (0.47) | USP2TSHRCYP3A4HSD17B10TACR1 | |
| SCHEMBL5014226 | 0.89 | HIF1A (0.47) | USP2TSHRCYP3A4HSD17B10TACR1 | |
| SCHEMBL5012567 | 0.89 | TACR1 (0.50) | USP2TSHRCYP3A4HSD17B10TACR1 | |
| SCHEMBL5010933 | 0.88 | USP2 (0.47) | USP2TSHRCYP3A4HSD17B10TACR1 | |
| SCHEMBL5010932 | 0.88 | USP2 (0.47) | USP2TSHRCYP3A4HSD17B10TACR1 | |
| SCHEMBL5014308 | 0.86 | USP2 (0.48) | USP2TSHRCYP3A4HSD17B10TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390372-B1 | 1-OXA-3,9-DIAZA-SPIRO'5,5]UNDECAN-2-ONES DERIVATIVES AND ITS USE AS ANTAGONIST OF THE NEURIKININ RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-07-16 | — | — | EP | claimed |
| US-6599900-B2 | Antiinflammatory agents; headaches; antiarthritic agents | SYNTEX (U.S.A.) LLC | 2003-07-29 | — | — | US | claimed |
| EP-1390372-B1 | 1-OXA-3,9-DIAZA-SPIRO'5,5]UNDECAN-2-ONES DERIVATIVES AND ITS USE AS ANTAGONIST OF THE NEURIKININ RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-07-16 | — | — | EP | disclosed |
| US-6599900-B2 | Antiinflammatory agents; headaches; antiarthritic agents | SYNTEX (U.S.A.) LLC | 2003-07-29 | — | — | US | disclosed |
| US-20030004163-A1 | 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones | SYNTEX (U.S.A) LLC | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004163-A1 | 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones | OXER1, NR4A1, OXGR1 | USP2 4097/4885TSHR 298/4885CYP3A4 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.